Mr. Bill Ciprick reports

OPTIMI HEALTH ANNOUNCES CAD$1.2 MILLION GMP PSILOCYBIN SUPPLY AGREEMENT FOR CLINICAL RESEARCH AND DEVELOPMENT

Optimi Health Corp. has entered into a $1.2-million definitive supply agreement with a private entity focused on developing mushroom-based therapeutic drugs through preclinical research and clinical trials.

Under Canada's controlled drugs and substances regulations, Optimi functions as an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA), natural GMP (good manufacturing practice)-grade psilocybin and high-quality functional mushrooms.

To fulfill its obligations, Optimi is cultivating dried GMP psilocybin-containing biomass and extract into a refined substance, which will be distributed to the client's international research sites.

This announcement affirms Optimi's commitment to GMP production capabilities and its ability to supply large-scale research and development programs.

Bill Ciprick, Optimi's chief executive officer, said: "This is a big day for Optimi. To be selected as the singular supply entity in the sector capable of scaling to help fulfill the needs of our client reflects our ability to deliver substantial value to the research community and our shareholders."

Bryan Safarik, Optimi's chief operating officer and co-founder, said, "We will have more to say in the coming months, however, for now we are focused on execution as we work to establish a long-term, mutually beneficial relationship."

This latest agreement helps to fulfill the goal of Optimi's founders in making the company a true multinational participant in the research and development of psychedelic medicines.

Earnings results

Optimi plans to report its Q2 2023 earnings results before markets open on a date to be approved (between May 19 and May 30, 2023) by the company's audit committee.

About Optimi Health Corp.

Optimi Health is an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply psychedelic substances (such as 3,4-methylenedioxymethamphetamine (MDMA) and GMP-grade psilocybin) as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the company's goal is to be the No. 1 trusted, compassionate supplier of safe drug products throughout the world. Optimi's products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, B.C.

We seek Safe Harbor.